For Immediate Release
Chicago, IL -April 15, 2019 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Bank of America BAC , Amgen AMGN , NextEra Energy NEE , T-Mobile TMUS and S&P Global SPGI .
Here are highlights from Monday's Analyst Blog:
Top Analyst Reports for Bank of America, Amgen and NextEra
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Amgen and NextEra Energy. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Bank of America 's shares have outperformed the Zacks Major Regional Banks in the past six months, gaining +4.1% vs. -1.8%. The company possesses an impressive earnings surprise history, beating expectations in each of the trailing four quarters. Earnings estimates have been going down ahead of the company's first quarter 2019 results.
The Zacks analyst thinks the bank's initiatives to expand into new markets and digital offerings will likely further enhance cross-selling opportunities. Moreover, the rise in loan and deposit balances, higher interest rates and efforts to control expenses will likely support profitability.
However, the dismal performance of capital markets has been hurting the company's investment banking operations. Further, litigation issues related to its misconduct in the pre-crisis period are likely to lead to an increase in legal expenses, thereby hurting the bottom line to some extent.
Shares of Buy-ranked Amgen have declined -1.3% year to date, underperforming the Zacks Biomedical and Genetics industry's increase of +9.3%. The Zacks analyst thinks that while Amgen's newer drugs - Prolia, Xgeva, Blincyto, Kyprolis - will drive sales, biosimilar and brand competition faced by its legacy drugs will create pressure on the top line in 2019.
Meanwhile, uptake of key drug, Repatha has been slow due to payer restrictions. However, Amgen is progressing well with its pipeline and approval of Aimovig was a huge boost. In the past five years, Amgen has launched nine products, including two in new therapeutic areas. Amgen boasts a strong biosimilars pipeline, which could be an important long-term growth driver for the company.
Amgen's restructuring plan is making it leaner and more cost-efficient. Lower taxes and share buybacks should provide some support to the bottom line. Estimates have declined lightly ahead of the Q1 earnings release. Amgen has a positive record o f earnings surprises in recent quarters.
(You can read the full research report on Amgen here >>> ).
NextEra Energy 's shares have outperformed the Zacks Electric Power industry in the past year, gaining +18.6% vs. +14.3%. The Zacks analyst thinks NextEra Energy's strategic investments to strengthen infrastructure, expansion of renewable operations and ongoing capital projects, on completion, will help in serving the company's expanding customer base more efficiently.
Focus on expanding operation in natural gas pipelines will boost its performance, as demand for midstream services is increasing in the United States. The company's expansion of business through acquisitions positively impacted earnings. However, its nature of business is subject to complex and comprehensive federal, state, and other regulations.
Substantial investments are undertaken to ensure the safety of nuclear operations. That said, if planned outages last longer than expected or there is an unplanned outage, the company's normal operations and profitability might be hindered.
Other noteworthy reports we are featuring today include T-Mobile and S&P Global.
Radical New Technology Creates $12.3 Trillion Opportunity
Imagine buying Microsoft stock in the early days of personal computers… or Motorola after it released the world's first cell phone. These technologies changed our lives and created massive profits for investors.
Today, we're on the brink of the next quantum leap in technology. 7 innovative companies are leading this "4th Industrial Revolution" - and early investors stand to earn the biggest profits.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss . This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
NextEra Energy, Inc. (NEE): Free Stock Analysis Report
Bank of America Corporation (BAC): Free Stock Analysis Report
S&P Global Inc. (SPGI): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
T-Mobile US, Inc. (TMUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of NASDAQ, Inc.